P.A.W. Capital’s ChemoCentryx, Inc. CCXI Stock Holding History

P.A.W. Capital’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-60,000	Closed	-$558K	–	65
2019 Q2	$558K	Buy	+60,000	New	+$695K	0.6%	56
2019 Q1	–	Sell	-50,000	Closed	-$546K	–	65
2018 Q4	$546K	Sell	50,000 -40,000	-44%	-$422K	0.68%	51
2018 Q3	$1.14M	Buy	90,000 +5,000	+6%	+$60.2K	1.21%	26
2018 Q2	$1.12M	Buy	85,000 +10,000	+13%	+$120K	1.13%	28
2018 Q1	$1.02M	Sell	75,000 -85,000	-53%	-$877K	1.23%	27
2017 Q4	$952K	Hold	160,000	–	–	1.2%	30
2017 Q3	$1.19M	Hold	160,000	–	–	1.24%	31
2017 Q2	$1.5M	Hold	160,000	–	–	1.5%	33
2017 Q1	$1.17M	Buy	160,000 +40,000	+33%	+$288K	1.18%	36
2016 Q4	$888K	Buy	120,000 +30,000	+33%	+$216K	1%	37
2016 Q3	$544K	Sell	90,000 -60,000	-40%	-$284K	0.59%	61
2016 Q2	$674K	Buy	+150,000	New	+$563K	0.77%	47

Other funds holding CCXI

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

P.A.W. Capital's CCXI Position: Q3 2019 in Review

P.A.W. Capital sold out of ChemoCentryx, Inc. (CCXI) in Q3 2019, closing a stake of 60,000 shares — an estimated $558K sold.

P.A.W. Capital first reported a position in CCXI in Q2 2016 and held it in 12 quarters. The position peaked at $1.5M in Q2 2017. 100 funds tracked by Wall St. Rank hold CCXI as of Q3 2019.

P.A.W. Capital reported no remaining ChemoCentryx, Inc. position as of Q3 2019 after selling out during the quarter.
P.A.W. Capital sold 60,000 ChemoCentryx, Inc. shares in Q3 2019, an estimated $558K.
P.A.W. Capital first reported a position in ChemoCentryx, Inc. in Q2 2016 and held it in 12 quarters.
P.A.W. Capital's ChemoCentryx, Inc. position peaked at $1.5M in Q2 2017.
100 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2019.

Based on P.A.W. Capital's 13F filing for Q3 2019, filed 30 Oct 2019.